TP53 and neoplasm: Although patients frequently harboured point mutations in the DNA-binding domain of TP53 affecting well-known hotspot sites28, gene-damaging alterations occurred in 40% of patients and we confirmed either truncated or absent protein products in tumours of these patients (Fig. 5a and Extended Data Fig. 9a).